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Abstract  
Vitamin D is a steroid hormone that in addition to its well known role in the metabolism of calcium 
and phosphorus exerts immunoregulatory properties. Data from animal studies and from 
prospective clinical trials on patients with rheumatoid arthritis, multiple sclerosis and type 1 diabetes 
point to the potential role of vitamin D as important environmental factor in the development of 
autoimmune diseases. Such role of vitamin D in systemic lupus erythematosus (SLE) has not yet 
been sufficiently studied. This review shows the sources, metabolism and mechanism of action of 
vitamin D, its effect on the cells of the immune system, prevalence and causes of vitamin D 
deficiency in patients with SLE, the link between vitamin D status and disease activity as well as 
recommendations for vitamin D supplementation. 
 
 
 
 
 
 
 
Introduction 
 
Systemic lupus erythematosus (SLE) is a 
systemic autoimmune disease of unknown etiology. 
Numerous genetic, hormonal and environmental 
factors are involved in the development of this 
disease. Lately, more attention is given to vitamin D 
as a potential environmental factor in pathogenesis of 
SLE. It is a steroid hormone that plays a key role in 
the metabolism of calcium, phosphorus and bone 
homeostasis. Also important is its role in the function 
of muscular, cardiovascular and immune system, as 
well as in the processes of reproduction, growth and 
cell differentiation. There is increasing evidence on 
the role of vitamin D deficiency in the development of 
autoimmune, neoplastic and cardiovascular diseases. 
In recent decades a significant increase in the 
prevalence of vitamin D deficiency in the general 
population has been evident. The reasons for this are 
insufficient exposure to sunlight, use of sunscreens, 
and insufficient intake of vitamin D through food [1]. 
Patients with SLE are particularly prone to developing 
a vitamin D deficiency. One explanation is a strict 
fotoprotection they are advised due to 
photosensitivity. 
Sources, metabolism and mechanism of 
action of vitamin D  
 
Vitamin D was discovered in 1913 by 
McCollum and Davis, along with many other vitamins, 
and the name is still retained although later research 
showed that vitamin D is actually prohormone [2]. The 
main source of vitamin D is an endogenous synthesis 
in the skin after exposure to ultraviolet B light (UVB 
290-315 nm) (Figure 1). This process is influenced by 
numerous factors: season, latitude, skin pigmentation 
and sunscreen use. Smaller amounts of vitamin D 
come through food and supplements. The sun's UVB 
rays penetrate the skin and lead to the conversion of 
7-dehydrocholesterol into previtamin D3, which is then 
spontaneously converted to vitamin D3 (cholecalci-
ferol) which enters the circulation. Excess previtamin 
D3 or vitamin D3 is degraded under the influence of 
sunlight, so that even intense exposure to sunlight 
does not lead to vitamin D intoxication. Dietary vitamin 
D comes from foods and supplements in the form of 
vitamin D3 or vitamin D2. Few foods (e.g. salmon, 
tuna, sardines, egg yolk) naturally contain and some 
(e.g. milk, butter, orange juice, cheeses, infant 
formulas) are fortified with vitamin D. Vitamin D2 is 
produced through ultraviolet irradiation of ergosterol 
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from yeast and vitamin D3 through ultraviolet 
irradiation of 7-dehydrocholesterol from lanolin. Both 
types of vitamins have identical metabolism. Vitamin 
D from foods or supplements is incorporated into 
chylomicrons and enters circulation through the 
lymphatic system. It becomes biological active after a 
gradual process of hydroxylation in the liver and 
kidneys, during which 1,25-dihydroxy-vitamin D 
(1,25(OH)2D) is created. The production of 
1,25(OH)2D is regulated by concentrations of 
parathyroid hormone, calcium and phosphorus and 
1,25(OH)2D itself. A number of autocrine and 
paracrine actions of vitamin D are described too. In 
fact, the presence of the enzyme 1-α-hydroxylase 
(which catalyses the final stage of activation of vitamin 
D) has been shown in other tissues: lung, placenta, 
colon, β-cells of the pancreas, parathyroid gland and 
in many immune cells [3]. Majority of biological effects 
of 1,25(OH)2D are achieved by binding to the 
widespread vitamin D receptor (VDR). Its presence 
has been identified in a number of cells: osteoblasts, 
cells of renal tubules and parathyroid glands, 
keratinocytes, promyelocytes, lymphocytes, epithelial 
cells of the colon, enterocytes, cells of the pituitary 
gland and ovary [1]. Binding of 1,25(OH)2D to the 
VDR results in interreaction with the vitamin D 
responsive elements in the promoter region of vitamin 
D-responsive genes, thereby regulating the level of its 
transcription (slow genomic effects). By direct or 
indirect regulation of expression of over 200 genes, 
1,25(OH)2D regulates cell proliferation, differentiation, 
apoptosis and angiogenesis. Both, in normal cells and 
tumor cells vitamin D reduces cell proliferation and 
promotes terminal differentiation. Also, 1,25(OH)2D 
inhibits renin synthesis, increases the production of 
insulin and myocardial contractility [4, 5]. An additional 
mechanism of action of 1,25(OH)2D independent of 
gene transcription is assumed (fast non-genomic 
effects), which is achieved through modulation of 
intracellular signaling pathways [1, 6]. 
 
 
Determination of vitamin D status  
 
Vitamin D status is determined by measuring 
the serum level of 25(OH)D. This is the major 
circulating form of vitamin D with the half-life of 
approximately three weeks. In contrast, 1,25(OH)2D 
has a short half-life and a very low serum level. There 
is no consensus on optimal 25(OH)D level. The 
majority of authors consider a serume level greater 
than 30ng/ml sufficient (conversion factor to nmol/l is 
2.496). Vitamin D insufficiency is defined as a serum 
level of 25(OH)D between 21 and to 29 ng/ml, and 
values less than 20 ng/ml are considered as vitamin D 
deficiency [1, 6, 7]. These values are established in 
relation to the effects of vitamin D on calcium 
metabolism and bone homeostasis and the regulatory 
response of parathyroid hormone. The 25(OH)D level 
required for optimal functioning of immune system is 
not known. There are several methods for measuring 
25(OH)D level: radioimmunoassay (RIA), electroche-
miluminescent immunoassay (ECLIA) and liquid 
chromatography, which many consider the gold 
standard [8]. 
 
Figure 1: Sources and metabolism of Vitamin D.  
 
 
Immunoregulatory properties of vitamin D  
 
The potential role of vitamin D in the immune 
system functioning is assumed in the 1980s after the 
discovery that antigen-presenting cells (APC) such as 
macrophages and dendritic cells (DCs) constitutively 
express VDR, while lymphocytes express VDR only 
after activation. Activated macrophages possess the 
enzyme 1-α-hydroxylase, which allows them to 
synthesize and secrete 1,25(OH)2D. However, unlike 
the 1-α-hydroxylase in the kidneys, which is regulated 
by parathormone and 1,25(OH)D, 1-α-hydroxylase in 
macrophages is controlled by the immune signals, 
primarily interferon gamma (IFN-γ). In addition, the 
hydroxylase in macrophages is not affected by the 
negative feedback of the 1,25(OH)2D, thus explaining 
intermittent hypercalcemia in conditions of excessive 
macrophage activation (e.g. sarcoidosis). Monocytes 
and macrophages possess 24-hydroxylase, an 
enzyme that breaks down 1,25(OH)2D. The activity of 
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this enzyme is highly dependent on the stage of 
activation/differentiation of monocytes and 
macrophages. The presence of the enzymes 
responsible for the metabolism of vitamin D in the 
cells of the immune system enables them to achieve 
high local 1,25(OH)2D level in the microenvironment 
of the lymph tissues, while also limiting the undesired 
systemic effects such as hypercalcemia [6, 9, 10].  
Quiescent CD4 + T cells express the VDR, and upon 
activation expression of VDR increases fivefold [11]. 
The overall effect of vitamin D on CD4 + T 
lymphocytes consists in the suppression of Th-1 and 
promoting Th-2 cellular response [12-14]. This is 
achieved through modulation of cytokine production 
and through direct effect on Th-1 lymphocytes.  
It has been shown that vitamin D facilitates the 
induction of Foxp3 + regulatory T cells [15].  
Regarding B lymphocytes, vitamin D inhibits the 
production of immunoglobulins (direct effect) and 
interrupts the process of their differentiation [16, 17]. 
Examination of peripheral blood mononuclear cells 
(PBMCs) of patients with SLE showed that adding 
vitamin D to the culture of PBMCs significantly 
reduces the production of polyclonal antibodies and 
anti-ds-DNA antibodies [18]. 
The most significant effect of vitamin D on the 
immune system is achieved by affecting the DCs [19-
22]. Its overall impact consists in promoting the 
creation of tolerogenic DCs. Kamen and Aranow 
showed that the MDCC in patients with SLE and in 
healthy individuals behave similarly in the presence of 
physiological concentrations of vitamin D. Lupus 
MDCC differentiated in the presence of vitamin D 
withhold unmature phenotype with inhibited 
expression of costimmulatory molecules HLADR, 
CD40 and CD86 [23]. 
Data collected by previous studies suggest 
that vitamin D has an overall inhibiting effect on the 
development of autoimmune diseases: suppresses 
the differentiation of DCs and Th-1 lymphocytes, 
stimulates T regulatory cells, reduces the production 
of autoantibodies and release of inflammatory 
mediators and possibly, leads to the re-establishment 
of autotolerance. 
 
 
Vitamin D and autoimmune diseases  
 
In numerous clinical studies a connection 
between vitamin D level and several autoimmune 
diseases is observed. Most data refers to the 
relationship between vitamin D level and multiple 
sclerosis, rheumatoid arthritis and inflammatory bowel 
disease [24, 25]. Large population studies (the 
Nurses’ Health Study I and II) showed that women 
with the highest vitamin D intake had a 40% lower risk 
for developing multiple sclerosis [26]. The Women's 
Iowa Health Study that included 29,368 women has 
demonstrated an inverse relationship between 
increased intake of vitamin D and the occurrence of 
rheumatoid arthritis [27]. Experimental studies on 
animal models have shown that vitamin D deficiency 
can lead to exacerbation of inflammatory bowel 
disease and multiple sclerosis [28]. Moreover, it has 
been demonstrated that the use of vitamin D 
suppresses the occurrence of multiple sclerosis and 
inflammatory bowel disease in experimental models in 
mice [29]. 
 
 
Vitamin D and SLE  
 
Reduced concentration of vitamin D is found 
in the serum of patients with SLE. Possible causes of 
vitamin D deficiency in patients with SLE are 
photosensitivity, application of sunscreen with high 
sun protection factor, kidney damage, chronic use of 
glucocorticoids and antimalarials [30, 31]. Vitamin D 
deficiency is often asymptomatic. Symptoms, if they 
occur, are non-specific and usually manifest as 
musculoskeletal pain, paresthesia and cramps, which 
are often present in patients with SLE regardless of 
vitamin D deficiency. 
Studies on several animal models of SLE 
have shown that vitamin D supplementation can lead 
to the improvement of various disease manifestations, 
including the reduction of proteinuria [32, 33] and 
even to the reduction of the risk for developing SLE 
[32]. Approximately 50% of patients with SLE show a 
specific pattern of gene expression called "interferon 
signature" which correlates with disease activity. The 
main source of interferon-α are plasmacytoid DCs, 
that release this cytokine upon stimulation by immune 
complexes containing nucleic acid. It is shown that 
plasma of patients with SLE may induce "interferon 
signature" in normal peripheral blood lymphocytes and 
that vitamin D suppresses the expression of  
"interferon signature" in MDDC of patients with SLE 
[23]. This finding suggests a possible application of 
vitamin D in therapy of SLE. 
 
 
Prevalence of vitamin D deficiency in SLE  
Literature data show a high prevalence of 
vitamin D deficiency in patients with SLE [31, 34-40]. 
One of the first studies which demonstrated the 
presence of low vitamin D levels in patients with SLE, 
dates from 1979. In this study, decreased 
concentration of 1,25(OH)2D was found in 7 of 12 
adolescents treated with glucocorticoid drugs [41]. 
Kamen and colleagues compared serum levels of 
25(OH)D in 123 patients with newly diagnosed SLE 
with levels of 240 healthy controls, matched by age 
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and sex. The mean 25(OH)D level in a group of SLE 
patients was 21.6ng/ml and in the control group 27.4 
ng/ml. Overall, it was found that 67% of patients with 
SLE have vitamin D deficiency. Critically low 25(OH)D 
level (< 10 ng/ml) was found in 22 patients, with 
presence of renal disease and photosensitivity being 
the strongest predictor [31].  The Israelian study that 
measured  25(OH)D level in a number of autoimmune 
diseases, showed that  SLE patients had significantly 
lower levels (11.9 ng/ml) compared to European 
control (21.6 ng/ml) [43]. The group from Baltimore in 
a study  from 2013 found reduced 25(OH)D levels in 
76% of patients with SLE and the percentage was 
significantly higher in the population of African-
Americans (85%) and those aged 30-50 years (79 %) 
[43]. 
It is still not clear whether vitamin D deficiency 
precedes the occurrence of SLE or the disease itself 
contributes to vitamin D deficiency. Is vitamin D an 
enviromental factor important in the emergence and 
further course of SLE that we can influence? 
 
 
Vitamin D as a potential biomarker of SLE  
 
Several studies showed a trend of higher SLE 
activity in patients with vitamin D deficiency. 
According to the study that included 165 SLE patients 
in three centers, a significantly higher level of disease 
activity was found in those with severe vitamin D 
deficiency (25(OH)D ≤ 10 ng/mL) compared to those 
with less severe deficiency [44]. A significant negative 
correlation between 25(OH)D level and disease 
activity was found in the group of 46 patients from 
northern and southern Europe [24]. Chinese study on 
88 SLE patients showed a significant correlation 
between lower 1,25(OH)2D levels, but not the 
25(OH)D levels and disease activity [17]. Of particular 
interest are results of a study that included 378 
patients with SLE from Europe and Israel, where 
disease activity was measured using two scoring 
systems - SLEDAI and ECLAM in which significant 
negative correlation between disease activity and 
25(OH)D levels was found. In this study, patients with 
active disease (SLEDAI > 3 or ECLAM > 1) had 
significantly lower vitamin D levels. In those with 
inactive SLE serum 25(OH)D level was 62 nmol/L and 
it is assumed that this 25(OH)D level may have 
protective effect on the occurrence of relapse of SLE 
[46]. Mok et al. found a significant negative correlation 
between 25(OH)D level and clinical activity of SLE, 
the titer of anti-C1q and anti-dsDNA antibodies [46]. 
However, in a few studies, a connection between 
vitamin D level and SLE activity has not been 
demonstrated [42, 47, 48]. 
 
 
Vitamin D as a potential therapeutic agent 
in SLE  
 
The possible use of vitamin D and its 
synthetic analogues in the treatment of various 
autoimmune diseases, including SLE has been 
investigated in several studies. Ruiz-Irastorza and 
associates have examined the effects of application of 
oral supplements of vitamin D3 (600 IU/day and 800 
IU/day) in the SLE. After the second year of therapy, 
although all patients had higher 25(OH)D level, 71% 
of them were still vitamin D insufficient and there was 
no decrease in disease activity [47]. On the other 
hand, large randomized placebo-controlled study with 
267 patients with SLE, showed a significant 
improvement in the inflammatory and hemostatic 
markers, as well as in the disease activity after 12 
months of use 200 IU/day of vitamin D3 [49].  
There are ongoing studies that examine the efficacy 
and safety of different doses (800 IU, 2000 IU, 4000 
IU/day) of vitamin D in SLE patients [50, 51]. 
 
 
Recommendations for vitamin D 
supplementation in SLE patients  
 
There is no international consensus on 
optimal dose of supplements for correction of vitamin 
D deficiency. Oral supplements of vitamin D may be in 
the form of vitamin D3 (cholecalciferol), or in the form 
of vitamin D2 (ergocalciferol). The dose of vitamin D 
supplement required to achieve adequate 25(OH)D 
level depends on the initial serum concentration of 
25(OH)D and the presence of additional risk factors 
(use of glucocorticoids, antimalarials, renal lesions, 
malabsorption). For each 1ng/ml of deficit of 25(OH)D, 
a 100 IU/day of vitamin D should be added. In patients 
with severe vitamin D deficiency and additional risk 
factors application of loading dose (50,000 IU of 
vitamin D3 per week for 6-8 weeks) is advised, 
followed by maintenance dose (2000-4000 IU/day) 
[52-57]. A stable serum 25(OH)D level is expected to 
be achived in about 3 months, when first control 
measurement is recommended, and then it should be 
controled every 6 to 12 months. In recent years, there 
are attempts of personalized approach which involves 
the use of a certain formulas to calculate the required 
dose of supplements [57].  
 
Conclusion  
 
Vitamin D deficiency is common in patients 
with SLE. The evidence from basic, genetic and 
epidemiological studies are still insufficient to 
Review Article 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
  666                                                                                                                                                                                                                     http://www.mjms.mk/ 
http://www.id-press.eu/mjms/ 
 
establish a causal connection between vitamin D 
deficiency and the development of the SLE, as well as 
its  role in the further disease course. Randomized 
controlled studies on a large number of subjects and 
with sufficiently long follow-up are necessary in order 
to demonstrate the credibility of this connection and to 
determine the best formulation, dosage, and duration 
of supplementation, as well as potential side effects. 
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